|
|
 |
|
Viewing report
|
|
|
|
Infectious Disease Vaccines: Pricing and Reimbursement Strategies for Access to Emerging Markets
Decision Resources, Inc, June 2011
Vaccines are giving multinational pharmaceutical companies (MNCs) a vanguard to the opportunities in emerging markets, especially the BRIC countries (Brazil, Russia, India, and China). These dynamic markets boast large and growing populations, increasing expenditures on healthcare, infectious disease burdens that align with manufacturers’ in-line and emerging vaccine brands, and prioritization from healthcare purchasers that citizens have access to vaccines. Against this backdrop, MNCs will use several strategies to maintain and increase their positions in the vaccine market, including partnerships with nongovernmental organizations, alliances with domestic industries, and selective launch sequences for in-line and emerging vaccines.
Questions answered in this report:
- Emerging markets offer to the international pharmaceutical industry opportunities that are increasingly dwindling in the mature markets. How have funding and structural reforms changed the landscape of healthcare access and expenditures in emerging markets? What aspects of emerging markets’ economies, demographics, and healthcare systems are favorable for vaccine marketers? Who are the major purchasers of vaccines in BRIC countries?
- Just a handful of MNCs dominated the global vaccine market in 2010. What strategies have leading MNCs used to gain access to emerging markets? How important are emerging-market sales to MNCs’ current vaccine businesses? Will GlaxoSmithKline, Sanofi, Pfizer, and Merck retain their market-leading positions through 2017?
- Non-governmental organizations (NGOs) are an important conduit to emerging markets. How successful have MNCs been in partnering with NGOs to serve the BRIC markets? What are the implications of cut-rate supply contracts for MNCs’ global vaccine-pricing strategies? Are domestic vaccine producers from developing countries able to compete for NGO contracts?
- After a period of dormancy, the vaccine pipeline is once again active. What is the historic sales growth that feeds this renewed interest? What does the R&D pipeline hold, by indication and phase? What is the focus of clinical trial activity for vaccines in emerging markets? How have multinational vaccine companies crafted global launch strategies that maximize their positions in both emerging and mature markets?
Scope:
Markets covered: Brazil, Russia, India, and China. Also discussed: South Korea, Turkey, United States.
Healthcare system overviews: Healthcare reforms, expenditures, key providers, and purchasers in the BRIC countries.
Vaccine company strategies: Gaining market access for in-line and emerging vaccines; pricing strategies; launch patterns in developed and developing markets; partnerships with NGOs and domestic industry.
Vaccine development: Clinical pipeline, companies, clinical trials.
Market trends: Decision Resources’ Pharmaview analyst forecasts of market trends.
Outlook: Global vaccine sales in 2017; future position of current market-leading MNCs.
Exhibits: 19 tables/figures showing market data, BRIC country healthcare system details, immunization schedules, vaccine pipelines, deals between MNCs and emerging-market organizations.
|
|
|
|
